← Back to Search

Anti-metabolite

Combination Chemotherapy for Myelodysplastic Syndrome

Phase 2

Waitlist Available

Research Sponsored by ALZA

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Histologically confirmed poor risk myelodysplastic syndrome, including at least one of the following: bilineage cytopenia, unfavorable cytogenetic abnormalities, refractory anemia with excess blasts and/or refractory anemia with excess blast in transformation (greater than 5% blast), at least 0.5 on the International Prognostic Score System, no chronic myelomonocytic leukemia, no hypocellular myelodysplastic syndrome (marrow cellularity less than 30%)

Performance status ECOG 0-1

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is studying giving topotecan and cytarabine with amifostine to see how well it works in treating patients with myelodysplastic syndrome.

Who is the study for?

This trial is for adults (16+) with myelodysplastic syndrome, a bone marrow disorder that can lead to leukemia. Participants should have specific blood cell counts, no severe heart failure or certain types of leukemia, and must not be pregnant. They need an implanted right atrial catheter and agree to use contraception.Check my eligibility

What is being tested?

The study tests the effectiveness of combining two chemotherapy drugs, topotecan and cytarabine, with amifostine—a drug meant to reduce chemo side effects—in patients with myelodysplastic syndrome to see if this mix is better at killing cancer cells.See study design

What are the potential side effects?

Chemotherapy may cause nausea, fatigue, hair loss, increased risk of infection due to low blood cell counts. Amifostine might help protect against some chemo side effects but can also cause dizziness or allergic reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My blood disorder is considered high-risk due to specific poor indicators.

Select...

I am fully active or can carry out light work.

Select...

I am 16 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

ALZALead Sponsor

3 Previous Clinical Trials

288 Total Patients Enrolled

Henry C. Fung, MD, FRCPEStudy ChairCity of Hope Comprehensive Cancer Center

Media Library

Cytarabine (Anti-metabolite) Clinical Trial Eligibility Overview. Trial Name: NCT00003827 — Phase 2

Myelodysplastic Syndrome Research Study Groups:

Myelodysplastic Syndrome Clinical Trial 2023: Cytarabine Highlights & Side Effects. Trial Name: NCT00003827 — Phase 2

Cytarabine (Anti-metabolite) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00003827 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there a high level of risk associated with this treatment plan?

"While Phase 2 trials do not have data supporting efficacy, this team believes that the safety profile of the treatment falls at a 2."

Answered by AI

Are there any available appointments for this research project?

"No, this study is not currently looking for new participants. According to the information on clinicaltrials.gov, the last time this trial was active was December 3rd, 2013. Even though this particular study is not enrolling patients at the moment, there are 2823 other trials that are still recruiting individuals."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome

1999. "Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00003827.

All > Leukemia > Ic